Evidence map›Paper›PMID 31341709›Full record

ArticleNeurology. Clinical practice2019

Multiple sclerosis and sarcoidosis: A case for coexistence.

Charles Tyshkov, Siddharama Pawate, Michael J Bradshaw, Dorlan J Kimbrough, Tanuja Chitnis, Jeffrey M Gelfand, Lana Zhovtis Ryerson, Ilya Kister

Open access · bronzeAbstract read
In one paragraph

Article in Neurology. Clinical practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Charles TyshkovNew York University Langone Medical Center (CT, LZR, IK), Multiple Sclerosis Comprehensive Care Center, New York, NY; the Vanderbilt University Medical Center (SP), Neuroimmunology Division, Nashville, TN; the Brigham and Women's Hospital (MJB, DJK, TC), Massachusetts General Hospital, Harvard Medical School, Boston, MA; and the Division of Neuroinflammation and Glial Biology (JMG), UCSF Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA.
Siddharama PawateNew York University Langone Medical Center (CT, LZR, IK), Multiple Sclerosis Comprehensive Care Center, New York, NY; the Vanderbilt University Medical Center (SP), Neuroimmunology Division, Nashville, TN; the Brigham and Women's Hospital (MJB, DJK, TC), Massachusetts General Hospital, Harvard Medical School, Boston, MA; and the Division of Neuroinflammation and Glial Biology (JMG), UCSF Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA.
Michael J BradshawNew York University Langone Medical Center (CT, LZR, IK), Multiple Sclerosis Comprehensive Care Center, New York, NY; the Vanderbilt University Medical Center (SP), Neuroimmunology Division, Nashville, TN; the Brigham and Women's Hospital (MJB, DJK, TC), Massachusetts General Hospital, Harvard Medical School, Boston, MA; and the Division of Neuroinflammation and Glial Biology (JMG), UCSF Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA.
Dorlan J KimbroughNew York University Langone Medical Center (CT, LZR, IK), Multiple Sclerosis Comprehensive Care Center, New York, NY; the Vanderbilt University Medical Center (SP), Neuroimmunology Division, Nashville, TN; the Brigham and Women's Hospital (MJB, DJK, TC), Massachusetts General Hospital, Harvard Medical School, Boston, MA; and the Division of Neuroinflammation and Glial Biology (JMG), UCSF Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA.
Tanuja ChitnisNew York University Langone Medical Center (CT, LZR, IK), Multiple Sclerosis Comprehensive Care Center, New York, NY; the Vanderbilt University Medical Center (SP), Neuroimmunology Division, Nashville, TN; the Brigham and Women's Hospital (MJB, DJK, TC), Massachusetts General Hospital, Harvard Medical School, Boston, MA; and the Division of Neuroinflammation and Glial Biology (JMG), UCSF Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA.
Jeffrey M GelfandNew York University Langone Medical Center (CT, LZR, IK), Multiple Sclerosis Comprehensive Care Center, New York, NY; the Vanderbilt University Medical Center (SP), Neuroimmunology Division, Nashville, TN; the Brigham and Women's Hospital (MJB, DJK, TC), Massachusetts General Hospital, Harvard Medical School, Boston, MA; and the Division of Neuroinflammation and Glial Biology (JMG), UCSF Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA.
Lana Zhovtis RyersonNew York University Langone Medical Center (CT, LZR, IK), Multiple Sclerosis Comprehensive Care Center, New York, NY; the Vanderbilt University Medical Center (SP), Neuroimmunology Division, Nashville, TN; the Brigham and Women's Hospital (MJB, DJK, TC), Massachusetts General Hospital, Harvard Medical School, Boston, MA; and the Division of Neuroinflammation and Glial Biology (JMG), UCSF Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA.
Ilya KisterNew York University Langone Medical Center (CT, LZR, IK), Multiple Sclerosis Comprehensive Care Center, New York, NY; the Vanderbilt University Medical Center (SP), Neuroimmunology Division, Nashville, TN; the Brigham and Women's Hospital (MJB, DJK, TC), Massachusetts General Hospital, Harvard Medical School, Boston, MA; and the Division of Neuroinflammation and Glial Biology (JMG), UCSF Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA.
Harvard University · USMassachusetts General Hospital · USVanderbilt University Medical Center · USBrigham and Women's Hospital · USNYU Langone Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with biopsy-proven systemic sarcoidosis who develop a chronic CNS disorder are often presumed to have neurosarcoidosis (NS), however, the possibility of comorbid neurologic disease, such as MS, must be considered if presentation and course are not typical for NS.

methodsRetrospective chart review across 4 academic MS centers was undertaken to identify patients with diagnosis of MS (2017 McDonald criteria) and biopsy-confirmed extraneural sarcoidosis. Data were abstracted from each chart using a case report form that systematically queried for demographic, clinical, and paraclinical characteristics relevant to NS and MS.

resultsTen patients met our inclusion criteria (mean age 47.7 [±5.9] years; 80% female). Noncaseating granulomas consistent with sarcoidosis were found on biopsy in all cases (lung 7/10, mediastinum 2/10, liver 1/10, spleen 1/10, and skin 1/10). Diagnosis of MS was based on clinical history of MS-like relapses and MRI findings characteristic of demyelination and typical disease evolution during follow-up (average of 7 years). No patient developed features of NS that could be considered a "red flag" against the diagnosis of MS (such as meningeal enhancement, hydrocephalus, and pituitary involvement). All patients were treated with disease-modifying therapy for MS.

conclusionsWe propose a rational diagnostic approach to patients with sarcoidosis who may have comorbid MS. When the clinical picture is equivocal, the presence of multiple "MS-typical lesions" and the absence of any "NS-typical lesions" on MRI favor diagnosis of MS. Close follow-up is required to ascertain whether clinical and radiologic disease evolution and response to MS therapies conform to the proposed diagnosis of MS.

Identifiers

PMID31341709
PMCPMC6615652
OpenAlexW2937612179

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.